Xspray Pharma publishes Interim Report Q1, January-March 2019
May 16, 2019
”Over the past year, we’ve tripled the number of employees and I’m very pleased to see that our entire team is performing high quality work with great commitment. Xspray is today a company well-equipped to take a drug all the way to a finished product.”
Per Andersson, CEO Xspray Pharma AB (publ)
January–March 2019, Group
Because no Group existed during the same period in the previous year, there are no comparative figures.
• Net sales amounted to SEK 0 thousand
• Earnings before tax amounted to SEK -8,503 thousand
• Earnings per share before dilution amounted to SEK -0.56
• Cash flow from operating activities totaled SEK -12,451 thousand
• Cash and cash equivalents at the end of the period totaled SEK 192,850 thousand
• Total equity amounted to SEK 293,212 thousand
• The total number of shares is 15,076,460
January–March 2019, parent company
Amounts in brackets refer to the corresponding period for the previous year.
• Net sales amounted to SEK 0 thousand (0)
• Earnings before tax amounted to SEK -8,542 thousand (-1,596)
• Earnings per share before dilution amounted to SEK -0.57 (-0.12)
• Cash flow from operating activities totaled SEK -12,943 thousand (-3,264)
• Cash and cash equivalents at the end of the period totalled SEK 192,800 thousand (188,889)
• Total equity amounted to SEK 293,174 thousand (237,426)
• The total number of shares is 15,076,460
Significant events during the first quarter 2019
• Positive data from a clinical Phase 1 pilot study with the company’s product candidate HyNap-Sora, were presented in February
Significant events after the interim reporting period
• No significant events have taken place since the closing date
For further information, please contact:
Per Andersson, CEO, Xspray Pharma AB (publ)
Telephone: +46 (0)8 730 37 00
Email: per.andersson@xspray.com
The information was submitted for publication, through the agency of the contact person set out above, at 8:00 a.m. CET on May 16, 2019.
About Xspray Pharma
Xspray Pharma AB (publ) is a product development company with multiple product candidates in clinical development. Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.
The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered 39 in 2018. The company’s leading product candidates, HyNap-Dasa, HyNap-Sora and HyNap-Nilo, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Nexavar® (sorafenib) and Tasigna® (nilotinib), respectively. The launch of the first product candidate, HyNap-Dasa, is planned to take place in 2021. The substance patent for the original drug Sprycel® (dasatinib) expires at the end of 2020, and the secondary patents in 2026, which offers Xspray’s HyNap-Dasa a period of five years of semi-exclusivity before other competitors gain access to the market.
The company has patented manufacturing technology, equipment and the resulting products. The shares in Xspray Pharma are traded on Nasdaq First North Stockholm.
Xspray Pharma AB (publ)
Råsundavägen 12
169 67 Solna
info@xspray.com
Redeye AB is Xspray Pharma’s Certified Adviser
certifiedadviser@redeye.se
Telephone +46 (0)8 121 576 90